Research published in Frontiers of Medicine evaluates the human epidermal growth factor receptor 2 (HER2) status in extramammary Paget disease (EMPD) and explores the therapeutic potential of disitamab vedotin (DV), a novel humanized anti-HER2 antibody-drug conjugate (ADC), for this rare adenocarcinoma.
Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin
